A COST-UTILITY ANALYSIS OF TWO TRABECULAR MICRO-BYPASS STENTS IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA IN FRANCE
Author(s)
Nieland K1, Kleintjens J1, Gicquel G2, Falvey H3
1Pharmerit International, Rotterdam, Netherlands, 2Glaukos Corporation, Paris, France, 3Glaukos Corp, San Clemente, CA, USA
OBJECTIVES: To estimate the cost-utility of two micro-bypass trabecular stents (MBTS) implantation versus standard of care (SOC) of pharmacotherapy in the French healthcare setting. METHODS: A Markov model was designed to track progression of glaucoma through health states defined using Hodapp-Parrish-Anderson stages, mild, moderate, advanced, severe/blind, and death over a lifetime horizon. Reduction in intraocular pressure (IOP) and medication use due to MBTS and SOC were identified from randomized clinical trials and meta-analyzed. Transition probabilities were estimated using IOP-adjusted rate of decline in visual field (VF) loss. A 5% decline in relative treatment effect per year was assumed for extrapolation of efficacy beyond trial follow-up. Unit costs and resource use for France in 2018 were obtained from targeted literature reviews and expert advice. French claims data were acquired from MedicAM and used to estimate glaucoma medication costs with wastage, and medication persistence was extrapolated based on a recent French study. Probabilistic and one-way sensitivity analyses were conducted to estimate the impact of uncertainty on costs and quality-adjusted life years (QALYs). RESULTS: The meta-analysis shows a relative reduction in medication use by 1.13 drugs per patient in combination with a relative reduction of IOP by 1.10 mmHg at 36 months for MBTS compared to SOC. These outcomes lead to an estimated health gain of 0.154 QALYs and cost increase of €735 per patient, over a lifetime, leading to an ICUR of €4,760 per QALY gained. Sensitivity analyses showed that results were robust to variations in model assumptions. CONCLUSIONS: The cost of MBTS is partially offset by the decreased medication costs and lower rate of secondary procedures. Together with the expected quality of life gains, MBTS, such as iStent inject could be considered a cost-effective treatment option for patients with mild-to-moderate open-angle glaucoma in France.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PMD18
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Relating Intermediate to Long-term Outcomes, Trial-Based Economic Evaluation
Disease
Sensory System Disorders